Cargando…
A hypoxia-activated NO donor for the treatment of myocardial hypoxia injury
As present NO donor drugs cannot localize to release NO at the hypoxic site, along with the short half-life and bidirectional regulation of NO, they are unable to overcome low bioavailability and side effects in the treatment of myocardial hypoxia injury. In this study, we designed and prepared a no...
Autores principales: | Zhou, Wen, Yang, Wanxiang, Fan, Keyu, Hua, Wuyang, Gou, Shaohua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943891/ https://www.ncbi.nlm.nih.gov/pubmed/35432877 http://dx.doi.org/10.1039/d2sc00048b |
Ejemplares similares
-
A light-controlled multi-step drug release nanosystem targeting tumor hypoxia for synergistic cancer therapy
por: Zhang, Bin, et al.
Publicado: (2021) -
Hypoxia-Responsive Polymeric Micelles for Enhancing Cancer Treatment
por: Feng, Huayang, et al.
Publicado: (2020) -
Hypoxia-activated NIR photosensitizer anchoring in the mitochondria for photodynamic therapy
por: Xu, Feng, et al.
Publicado: (2019) -
HIF-stabilizing biomaterials: from hypoxia-mimicking to hypoxia-inducing
por: Colombani, Thibault, et al.
Publicado: (2023) -
Retracted Article: Knockdown of TUG1 aggravates hypoxia-induced myocardial cell injury via regulation of miR-144-3p/Notch1
por: Zhu, Bo, et al.
Publicado: (2019)